"Equip de professionals de la salut d'Atenció Primària que donem assistència a la població del Baix Guinardó. També som centre universitari i de recerca."

During the past decade, EAP Sardenya conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 6 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "EAP Sardenya" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Pfizer" with 2 trials sponsored, "Faes Farma, S.A." with 1 trials sponsored, "Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III" with 1 trials sponsored and "Janssen Research & Development, LLC" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "EAP Sardenya" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "ARTTIC International Management Services" with 1 trials as a collaborator, "Federación Argentina de Cardiología FAC" with 1 trials as a collaborator, "Ferrer Internacional S.A." with 1 trials as a collaborator and "Fundacion Clinic per a la Recerca Biomédica" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "EAP Sardenya" are "Diabetes Mellitus, Type 2" (3 trials), "Cardiovascular Disease" (2 trials), "Acute Respiratory Infection" (1 trials), "Diabetes Mellitus, Type 1" (1 trials) and "Myocardial Infarction" (1 trials). Many other conditions were trialed in "EAP Sardenya" in a lesser frequency.

Most popular intervention types in "EAP Sardenya" are "Drug" (8 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "bococizumab (PF-04950615)" (2 trials), "linagliptin" (2 trials), "BI 456906" (1 trials) and "Calcifediol 100mcg" (1 trials). Other intervention names were less common.

The vast majority of trials in "EAP Sardenya" are 9 trials for "All" genders.

Currently, there are NaN active trials in "EAP Sardenya". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in EAP Sardenya, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in EAP Sardenya, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".